Ronninge, Sweden

Tomas DePaulis


Average Co-Inventor Count = 7.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 1993

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Contributions of Tomas DePaulis

Introduction

Tomas DePaulis is a notable inventor based in Ronninge, Sweden. He has made significant contributions to the field of therapeutically active compounds. His work has led to the development of novel compounds that hold promise for various medical applications.

Latest Patents

Tomas DePaulis holds a patent for Oxysalicylamido derivatives. This patent describes novel therapeutically active compounds of the formula ##STR1## wherein Z.sup.i, being Z.sup.1, Z.sup.2 or Z.sup.3, is the same or different and selected among OH, OR.sup.1, NH.sub.2, NR.sub.2.sup.4, NHR.sup.4, SH, SR.sup.4 and OR.sup.4. In this formula, R.sup.1 is a formyl group, an acyl group, an alkoxycarbonyl group, or a mono- or dialkylcarbamoyl group, while R.sup.4 is a lower alkyl group. This patent showcases his innovative approach to creating new therapeutic agents.

Career Highlights

Tomas DePaulis is associated with Astra Lakemedel Aktiebolag, where he continues to contribute to the field of pharmaceuticals. His work at this company has allowed him to focus on the development of new therapeutic compounds that can potentially improve patient outcomes.

Collaborations

Throughout his career, Tomas has collaborated with notable colleagues, including Karl S Bengtsson and Thomas Hogberg. These collaborations have enriched his research and contributed to the advancement of innovative solutions in the pharmaceutical industry.

Conclusion

Tomas DePaulis is a distinguished inventor whose work in developing novel therapeutically active compounds has made a significant impact in the field of medicine. His contributions continue to inspire innovation and progress in pharmaceutical research.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…